EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study

Alex Soriano iD, Patrick M Honore iD, Oliver A Cornely iD, Methee Chayakulkeeree iD, Matteo Bassetti, Huang Haihui iD, Hervé Dupont iD, Young Keun Kim iD, Marin Kollef, Bart Jan Kullberg iD, Nick Manamley iD, Peter Pappas und 5 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae363 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Alex Soriano und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Caspofungin, Echinocandins, Antifungal Agents, Candidemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cidara Therapeutics, Mundipharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690). We conducted preplanned subgroup analyses for patients with a positive culture close to randomization in ReSTORE.

Methods

ReSTORE was a multicenter, double-blind, double-dummy, randomized trial in patients aged ≥18 years with candidemia and/or IC treated with once-weekly intravenous rezafungin (400 mg/200 mg) or once-daily intravenous caspofungin (70 mg/50 mg). This analysis comprised patients with a positive blood culture drawn between 12 hours before and 72 hours after randomization or a positive culture from another normally sterile site sampled between 48 hours before and 72 hours after randomization. Efficacy endpoints included day 30 ACM, day 14 global cure rate, and day 5 and 14 mycological response. Adverse events were evaluated.

Results

This analysis included 38 patients randomized to rezafungin and 46 to caspofungin. In the rezafungin and caspofungin groups, respectively, day 30 ACM was 26.3% and 21.7% (between-group difference [95% confidence interval], 4.6% [−13.7%, 23.5%]), day 14 global response was 55.3% and 50.0% (between-group difference, 5.3% [−16.1%, 26.0%]), and day 5 mycological eradication was 71.1% and 50.0% (between-group difference, 21.1% [−0.2%, 40.2%]). Safety was comparable between treatments.

Conclusions

These findings support the efficacy and safety of rezafungin compared with caspofungin for the treatment of candidemia and/or IC in patients with a positive culture close to randomization, with potential early treatment benefits for rezafungin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaspofunginEchinocandinsAntifungal AgentsCandidemiaCandidaHumansMaleFemaleMiddle AgedDouble-Blind MethodTreatment OutcomeAdultAgedCandidiasis, InvasiveCandidiasisYoung Adult

Stichwörter der Autor:innen

candidemiacaspofunginechinocandininvasive candidiasisrezafungin

Substanzen

CaspofunginEchinocandinsAntifungal AgentsRezafungin

Autor:innen und Institutionen

  • Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • CIBERINF, CIBER of Infectious Diseases, Madrid, Spain.
  • CHU UCL Godinne Namur, UCL Louvain Medical School, Campus Godinne, Namur, Belgium.
  • Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) and German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, University Hospital Cologne, Cologne, Germany.
  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Alex Soriano, Patrick M Honore, Oliver A Cornely, Methee Chayakulkeeree, Huang Haihui, Hervé Dupont, Young Keun Kim, Bart Jan Kullberg, Nick Manamley, Cecilia Dignani, Jose A Vazquez, George R Thompson

Förderung

  • Cidara Therapeutics
  • Mundipharma

Zitieren

APA

Soriano, A., Honore, P. M., Cornely, O. A., Chayakulkeeree, M., Bassetti, M., Haihui, H., Dupont, H., Kim, Y. K., Kollef, M., Kullberg, B. J., Manamley, N., Pappas, P., Pullman, J., Sandison, T., Dignani, C., Vazquez, J. A., & Thompson, G. R. (2024). Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae363

Vancouver

Soriano A, Honore PM, Cornely OA, Chayakulkeeree M, Bassetti M, Haihui H, et al. Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae363

BibTeX
@article{Soriano2024,
  author = {Soriano, Alex and Honore, Patrick M and Cornely, Oliver A and Chayakulkeeree, Methee and Bassetti, Matteo and Haihui, Huang and Dupont, Hervé and Kim, Young Keun and Kollef, Marin and Kullberg, Bart Jan and Manamley, Nick and Pappas, Peter and Pullman, John and Sandison, Taylor and Dignani, Cecilia and Vazquez, Jose A and Thompson, George R},
  title = {Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae363}
}
Kostenlos starten →